Triple negative breast cancer
Not recruitingA study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer
A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer
- Disease:Triple negative breast cancer
- Substances:DomvanalimabZimberelimab+1
Spain- Participants:18–64 years · 65+ years
- Substances:Domvanalimab
- Sponsor:Medica Scientia Innovation Research S.L.











